BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved antitumor activity
T. L. Hickman, E. Choi, K. R. Whiteman, S. Muralidharan, T. Pai, T. Johnson, A. Parikh, T. Friedman, M. Gilbert, B. Shen, L. Barron, K. E. McGinness, S. A. Ettenberg, G. T. Motz, G. J. Weiss, A. Jensen-Smith
This paper evaluates BOXR1030, a CAR T cell therapy co-expressing GPC3-targeted CAR and GOT2, showing enhanced T cell metabolism and improved antitumor activity in preclinical models.
bioRxiv · Nov 17, 2021 · PreprintCancer Biology